Oveporexton — Safety, Research, Risks & Legal Status

Not medical advice. Oveporexton is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	TAK-861
Category	Research Chemical
Developer	Takeda Pharmaceutical Company Limited
Development code	TAK-861
Drug class	Small-molecule OX2R-selective agonist (first-in-class)
Proposed indication	Narcolepsy type 1 (NT1)
Regulatory status (as of July 2026)	NDA accepted with FDA Priority Review; PDUFA goal date Q3 2026; not yet approved
Phase 3 programs	FirstLight (NCT05102955) and RadiantLight (NCT05266911) - both met all primary and secondary endpoints
US legal status	Not FDA-approved as of mid-2026. Investigational drug (IND status) developed by Takeda Pharmaceutical. An NDA was accepted by the FDA with Priority Review in February 2026, with a PDUFA goal date in Q3 2026. Not legally available for human use outside of clinical trials. Not a supplement or OTC product. Not for human consumption outside of supervised trial settings.

What is Oveporexton?

Oveporexton (TAK-861) is a small-molecule, orexin receptor 2 (OX2R)-selective agonist in late-stage clinical development for narcolepsy type 1 (NT1). It is designed to restore orexin signaling by directly agonizing OX2R, the receptor subtype most closely associated with wake-promotion and arousal. Narcolepsy type 1 is caused by the near-total loss of orexin-producing neurons; oveporexton addresses that deficit at the receptor level rather than managing downstream symptoms. It is the first selective OX2R agonist to reach late-stage human trials.

How it works

Oveporexton binds and activates the orexin 2 receptor (OX2R), a G-protein-coupled receptor expressed on wake-promoting neurons in the hypothalamus and basal forebrain. Endogenous orexin neuropeptides (orexin-A and orexin-B) are absent or severely depleted in NT1. By mimicking their action at OX2R - the subtype with the stronger wake-promotion signal - oveporexton is intended to reconstitute tonic arousal drive. This mechanistic approach is distinct from amphetamine-class stimulants (which act on monoamine transporters), modafinil (a weak dopamine reuptake inhibitor with unclear full mechanism), and sodium oxybate (a GABA-B and GHB receptor agonist acting on cataplexy and slow-wave sleep consolidation). OX2R selectivity is thought to reduce off-target effects associated with simultaneous OX1R agonism.

Background & history

Oveporexton was developed by Takeda Pharmaceutical Company Limited under the development code TAK-861. Its development follows the identification of orexin neuron loss as the root cause of NT1, a finding established in the early 2000s. Phase 2 clinical results were published in the New England Journal of Medicine (PMID 40367374), demonstrating statistically significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy frequency versus placebo. Two pivotal Phase 3 studies - FirstLight (NCT05102955) and RadiantLight (NCT05266911) - met all primary and secondary endpoints. Takeda filed an NDA that the FDA accepted with Priority Review in February 2026. As of July 2026, the PDUFA goal date falls in Q3 2026, with a planned commercial launch in H2 2026 contingent on approval.

What the research says

Clinical evidence base is substantially more developed than most compounds in this reference, reflecting late Phase 3 status. Phase 2 (TAK-861-2001, published in NEJM) showed wakefulness improvement of approximately 25 minutes on the Maintenance of Wakefulness Test, Epworth Sleepiness Scale improvements of 8.9-13.8 points, and cataplexy episode reductions of 70-75% versus placebo. A secondary analysis published in JAMA Neurology (PMID 41359331) examined cognitive outcomes, reporting improvements in attention, memory, and executive function measures - though these are secondary endpoints, not primary efficacy claims. Phase 3 results (FirstLight and RadiantLight studies) met all primary and secondary endpoints across wakefulness, sleepiness, cataplexy, attention, quality of life, and daily functioning. No hepatotoxicity was observed in clinical trials, which is a notable finding given that earlier OX2R-targeting compounds had raised hepatic safety signals. All published and reported efficacy data to date come from Takeda-sponsored trials; independent replication does not yet exist.

Reported effects

Increased wakefulness and reduced excessive daytime sleepiness in NT1 patients (Phase 2/3 clinical trial data)
Significant reduction in cataplexy episode frequency (Phase 2: 70-75% reduction versus placebo)
Improved Maintenance of Wakefulness Test scores (approximately 25-minute improvement in Phase 2)
Reduced Epworth Sleepiness Scale scores (8.9-13.8 point improvement in Phase 2)
Secondary cognitive improvements in attention, memory, and executive function reported in JAMA Neurology secondary analysis
Improved quality of life and daily functioning measures in Phase 3 (secondary endpoints)

Dosing & administration (informational)

Dosing information in the public domain is limited to what has been disclosed in clinical trial publications and regulatory communications. The Phase 2 NEJM publication (PMID 40367374) describes dose ranges evaluated in that study. Approved dosing, if the NDA is granted, would be established by the FDA label. This entry does not provide dosing guidance. Any dosing question should be directed to a licensed clinician familiar with sleep medicine and the evolving regulatory status of this compound.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Most common adverse events in Phase 2/3: insomnia (approximately 48%), urinary urgency (approximately 33%), urinary frequency (approximately 32%)
Insomnia was reported to be mostly self-resolving within approximately one week of treatment initiation
No hepatotoxicity detected in clinical trials, distinguishing oveporexton from some earlier OX2R-targeting compounds
No serious treatment-related adverse events reported in available trial data
Full long-term safety profile is not yet established; post-marketing data will not exist until and unless FDA approves the NDA
Safety data derive entirely from Takeda-sponsored trials; independent safety assessment is not yet available
Not for use outside clinical trial settings; no information available on safety in populations beyond those enrolled in NT1 trials

Drug & supplement interactions

N
o
p
u
b
l
i
c
l
y
a
v
a
i
l
a
b
l
e
c
o
m
p
r
e
h
e
n
s
i
v
e
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
s
a
s
o
f
J
u
l
y
2
0
2
6
.
I
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
C
N
S
s
t
i
m
u
l
a
n
t
s
u
s
e
d
i
n
n
a
r
c
o
l
e
p
s
y
(
a
m
p
h
e
t
a
m
i
n
e
s
,
m
o
d
a
f
i
n
i
l
,
a
r
m
o
d
a
f
i
n
i
l
)
,
s
o
d
i
u
m
o
x
y
b
a
t
e
,
a
n
d
o
t
h
e
r
a
g
e
n
t
s
a
f
f
e
c
t
i
n
g
o
r
e
x
i
n
s
i
g
n
a
l
i
n
g
o
r
a
r
o
u
s
a
l
c
i
r
c
u
i
t
s
h
a
v
e
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
p
u
b
l
i
s
h
e
d
l
i
t
e
r
a
t
u
r
e
.
A
s
a
n
o
r
e
x
i
n
a
g
o
n
i
s
t
,
a
d
d
i
t
i
v
e
o
r
s
y
n
e
r
g
i
s
t
i
c
w
a
k
e
f
u
l
n
e
s
s
e
f
f
e
c
t
s
w
i
t
h
s
t
i
m
u
l
a
n
t
s
a
r
e
p
l
a
u
s
i
b
l
e
.
U
r
i
n
a
r
y
a
d
v
e
r
s
e
e
v
e
n
t
s
s
u
g
g
e
s
t
p
o
s
s
i
b
l
e
r
e
l
e
v
a
n
c
e
i
n
p
a
t
i
e
n
t
s
o
n
m
e
d
i
c
a
t
i
o
n
s
a
f
f
e
c
t
i
n
g
b
l
a
d
d
e
r
f
u
n
c
t
i
o
n
.
C
o
n
s
u
l
t
t
h
e
p
r
e
s
c
r
i
b
i
n
g
l
a
b
e
l
i
f
a
n
d
w
h
e
n
t
h
e
c
o
m
p
o
u
n
d
i
s
a
p
p
r
o
v
e
d
.

Who should avoid it

Use outside of supervised clinical trial or (post-approval) licensed prescribing contexts
Concurrent use with other CNS stimulants without clinical supervision given risk of additive arousal effects
Assuming the adverse event profile characterized in NT1 trials applies to healthy individuals or other populations
Sourcing from any commercial or gray-market supplier - no legitimate non-trial supply exists
Equating Priority Review designation with approval - Priority Review accelerates FDA review timeline, it does not guarantee approval

How it is commonly combined

Not applicable in any evidence-based sense. Oveporexton has been studied as a standalone intervention in NT1 trials. No published data characterizes combinations with other wake-promoting agents, and no combination regimens have been evaluated in the available trial literature. Do not extrapolate from mechanism alone to predict safety or efficacy of combinations.

Legal & regulatory. Not FDA-approved as of mid-2026. Investigational drug (IND status) developed by Takeda Pharmaceutical. An NDA was accepted by the FDA with Priority Review in February 2026, with a PDUFA goal date in Q3 2026. Not legally available for human use outside of clinical trials. Not a supplement or OTC product. Not for human consumption outside of supervised trial settings.

Quality & harm reduction

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Find Oveporexton →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is oveporexton FDA-approved?

Not as of July 2026. Takeda filed an NDA that the FDA accepted with Priority Review in February 2026. The PDUFA goal date is Q3 2026. A regulatory decision has not been issued; the compound remains investigational.

How does oveporexton differ from modafinil or sodium oxybate?

Modafinil is a dopamine reuptake inhibitor that promotes wakefulness downstream of orexin neurons but does not restore orexin signaling. Sodium oxybate consolidates slow-wave sleep and reduces cataplexy via GABA-B and GHB receptor activity. Oveporexton directly agonizes OX2R, aiming to replace the function of lost orexin neurons rather than manage individual downstream symptoms. This represents a mechanistically distinct approach, though head-to-head comparative efficacy trials have not been published.

What does the OX2R selectivity mean clinically?

OX1R and OX2R have partially overlapping but distinct distributions and functions. OX2R is more closely associated with wake-promotion. Selective OX2R agonism is hypothesized to provide arousal benefits while reducing OX1R-mediated effects. Whether this selectivity translates into a clinically meaningful safety or efficacy advantage over non-selective agonism has not been definitively established in comparative studies.

What are the most commonly reported side effects from the trials?

In published Phase 2 and reported Phase 3 data, the most common adverse events were insomnia (approximately 48%, described as largely resolving within one week), urinary urgency (approximately 33%), and urinary frequency (approximately 32%). No serious treatment-related adverse events were reported, and no hepatotoxicity was detected. This is a Takeda-sponsored trial dataset; independent safety characterization is not available.

Can I obtain oveporexton now, before FDA approval?

No legitimate source exists outside of Takeda's clinical trial program. The compound is investigational. Any material sold commercially as oveporexton would be of unverified identity and purity. Expanded access or compassionate use pathways, if available, would require engagement with Takeda and a licensed clinician.

What is Priority Review, and does it guarantee approval?

Priority Review is an FDA designation indicating the drug may provide significant improvement in safety or effectiveness for a serious condition. It shortens the standard review timeline from 10 months to approximately 6 months. It does not guarantee approval; the FDA still conducts a full review of safety, efficacy, and manufacturing data before issuing a decision.

References & further reading

PubMed PMID 40367374 - Phase 2 efficacy and safety trial results, New England Journal of Medicine
PubMed PMID 41359331 - Cognitive effects secondary analysis, JAMA Neurology
ClinicalTrials.gov NCT05102955 - FirstLight Phase 3 study (TAK-861-3001)
ClinicalTrials.gov NCT05266911 - RadiantLight Phase 3 study (TAK-861-3002)
Takeda Pharmaceutical press release: FDA accepts NDA for oveporexton with Priority Review, February 2026 (search: Takeda oveporexton NDA Priority Review 2026)